Baiyunshan: Kegangli Throat Relief Oral Solution Enters Phase III Clinical Trials

Deep News

Oct 19

Baiyunshan (00874) announced that its subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. ("Wanglaoji Pharmaceutical"), recently held a launch meeting for the Phase III clinical trial of Kegangli Throat Relief Oral Solution for the treatment of acute pharyngitis (due to exterior wind-heat syndrome), marking the official commencement of this trial.

Kegangli Throat Relief Oral Solution received its new drug certificate and production license in 1997 and is exclusively produced by Wanglaoji Pharmaceutical. It is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China, featuring properties of dispelling wind, clearing heat, and detoxifying, primarily used for colds related to wind-heat exterior invasion and internal heat disturbance. In February 2024, Wanglaoji Pharmaceutical obtained the "Clinical Trial Approval Notice" from the National Medical Products Administration, granting permission to conduct a confirmatory clinical trial for acute pharyngitis (due to exterior wind-heat syndrome), specifically the Phase III clinical trial. Wanglaoji Pharmaceutical has recently officially launched this Phase III clinical trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104906445"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104906445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104906445?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-19 15:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104906445","market":"fut","top_or_hot":-1,"title":"Baiyunshan: Kegangli Throat Relief Oral Solution Enters Phase III Clinical Trials","media":"Deep News","content":"<p>Baiyunshan (00874) announced that its subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. (\"Wanglaoji Pharmaceutical\"), recently held a launch meeting for the Phase III clinical trial of Kegangli Throat Relief Oral Solution for the treatment of acute pharyngitis (due to exterior wind-heat syndrome), marking the official commencement of this trial.</p>\n<p>Kegangli Throat Relief Oral Solution received its new drug certificate and production license in 1997 and is exclusively produced by Wanglaoji Pharmaceutical. It is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China, featuring properties of dispelling wind, clearing heat, and detoxifying, primarily used for colds related to wind-heat exterior invasion and internal heat disturbance. In February 2024, Wanglaoji Pharmaceutical obtained the \"Clinical Trial Approval Notice\" from the National Medical Products Administration, granting permission to conduct a confirmatory clinical trial for acute pharyngitis (due to exterior wind-heat syndrome), specifically the Phase III clinical trial. Wanglaoji Pharmaceutical has recently officially launched this Phase III clinical trial.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan: Kegangli Throat Relief Oral Solution Enters Phase III Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan: Kegangli Throat Relief Oral Solution Enters Phase III Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-19 15:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Baiyunshan (00874) announced that its subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. (\"Wanglaoji Pharmaceutical\"), recently held a launch meeting for the Phase III clinical trial of Kegangli Throat Relief Oral Solution for the treatment of acute pharyngitis (due to exterior wind-heat syndrome), marking the official commencement of this trial.</p>\n<p>Kegangli Throat Relief Oral Solution received its new drug certificate and production license in 1997 and is exclusively produced by Wanglaoji Pharmaceutical. It is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China, featuring properties of dispelling wind, clearing heat, and detoxifying, primarily used for colds related to wind-heat exterior invasion and internal heat disturbance. In February 2024, Wanglaoji Pharmaceutical obtained the \"Clinical Trial Approval Notice\" from the National Medical Products Administration, granting permission to conduct a confirmatory clinical trial for acute pharyngitis (due to exterior wind-heat syndrome), specifically the Phase III clinical trial. Wanglaoji Pharmaceutical has recently officially launched this Phase III clinical trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"","article_id":"1104906445","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104906445","pubTimestamp":1760858433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Baiyunshan (00874) announced that its subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. (\"Wanglaoji Pharmaceutical\"), recently held a launch meeting for the Phase III clinical trial of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK4134":"信息科技咨询与其它服务","BK0028":"国家队","BK1191":"制药","00874":"白云山","BK0175":"白马股","BK0188":"融资融券","BK1515":"抗疫概念","BK0070":"员工持股","BK1606":"中医药概念","BK0196":"行业龙头","BK0097":"医药电商","BK0239":"医药制造","BK1197":"保健护理产品经销商","BK1521":"挪威政府全球养老基金持仓","BK0096":"民营医院","BK0183":"MSCI概念","III":"信息服务","BK0012":"证金概念"},"translate_title":"白云山：克刚力利咽口服液进入Ⅲ期临床","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"00874":1,"III":1},"content_text":"Baiyunshan (00874) announced that its subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. (\"Wanglaoji Pharmaceutical\"), recently held a launch meeting for the Phase III clinical trial of Kegangli Throat Relief Oral Solution for the treatment of acute pharyngitis (due to exterior wind-heat syndrome), marking the official commencement of this trial.\nKegangli Throat Relief Oral Solution received its new drug certificate and production license in 1997 and is exclusively produced by Wanglaoji Pharmaceutical. It is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China, featuring properties of dispelling wind, clearing heat, and detoxifying, primarily used for colds related to wind-heat exterior invasion and internal heat disturbance. In February 2024, Wanglaoji Pharmaceutical obtained the \"Clinical Trial Approval Notice\" from the National Medical Products Administration, granting permission to conduct a confirmatory clinical trial for acute pharyngitis (due to exterior wind-heat syndrome), specifically the Phase III clinical trial. Wanglaoji Pharmaceutical has recently officially launched this Phase III clinical trial.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}